Protagenic Therapeutics, Inc.\new Increase (Decrease) in Accounts Payable
Protagenic Therapeutics, Inc.\new (PTIX) reported Increase (Decrease) in Accounts Payable of $50.17 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $50.17K, a 81.07% decline year-over-year.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $827.33K.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $388.75K, a 47.06% increase year-over-year.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$442.19K.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for fiscal 2026 was $1.04M, a 470.58% increase from fiscal 2025.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for fiscal 2025 was $182.08K.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for fiscal 2015 was $30.00K.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accounts payable for fiscal 2014 was -$33.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.17K 10-Q · filed 2026-08-19 | $877.50K derived: sum of 2 quarters · filed 2026-08-19 | $1.27M derived: sum of 3 quarters · filed 2026-08-19 | $824.06K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $827.33K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $1.22M derived: sum of 2 quarters · filed 2026-08-14 | $773.89K derived: sum of 3 quarters · filed 2026-08-14 | $1.04M 10-K · filed 2026-08-14 |
| 2025-12-31 | $388.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | -$53.44K derived: sum of 2 quarters · filed 2026-03-09 | $211.57K 10-Q · filed 2026-03-09 | $133.67K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | -$442.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-26 | -$177.18K 10-Q · filed 2025-11-26 | -$255.08K derived: sum of 3 quarters · filed 2026-08-19 | $9.27K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $265.01K 10-Q · filed 2026-08-19 | $187.11K derived: sum of 2 quarters · filed 2026-08-19 | $451.46K derived: sum of 3 quarters · filed 2026-08-19 | $430.20K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$77.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $186.45K derived: sum of 2 quarters · filed 2026-08-14 | $165.19K derived: sum of 3 quarters · filed 2026-08-14 | $182.08K 10-K · filed 2026-08-14 |
| 2024-12-31 | $264.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $243.09K derived: sum of 2 quarters · filed 2026-03-09 | $259.98K 10-Q · filed 2026-03-09 | |
| 2024-09-30 | -$21.26K derived: 10-Q 6 month − 10-QT 3 month · filed 2025-11-26 | -$4.37K 10-Q · filed 2025-11-26 | ||
| 2024-06-30 | $16.89K 10-QT · filed 2025-09-10 | |||
| 2015-06-30 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25 | $4.00K derived: sum of 2 quarters · filed 2015-09-25 | $4.00K derived: sum of 3 quarters · filed 2015-09-25 | $30.00K 10-K · filed 2015-09-25 |
| 2015-03-31 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $8.00K derived: sum of 2 quarters · filed 2015-05-11 | $34.00K 10-Q · filed 2015-05-11 | $34.00K derived: sum of 4 quarters · filed 2015-09-25 |
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-06 | $26.00K 10-Q · filed 2015-02-06 | $26.00K derived: sum of 3 quarters · filed 2015-09-25 | -$5.00K derived: sum of 4 quarters · filed 2015-09-25 |
| 2014-09-30 | $26.00K 10-Q · filed 2014-11-13 | $26.00K derived: sum of 2 quarters · filed 2015-09-25 | -$5.00K derived: sum of 3 quarters · filed 2015-09-25 | $52.00K derived: sum of 4 quarters · filed 2015-09-25 |
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25 | -$31.00K derived: sum of 2 quarters · filed 2015-09-25 | $26.00K derived: sum of 3 quarters · filed 2015-09-25 | -$33.00K 10-K · filed 2015-09-25 |
| 2014-03-31 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $26.00K derived: sum of 2 quarters · filed 2015-05-11 | -$33.00K 10-Q · filed 2015-05-11 | |
| 2013-12-31 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-06 | -$2.00K 10-Q · filed 2015-02-06 | ||
| 2013-09-30 | -$59.00K 10-Q · filed 2014-11-13 | |||
| 2011-09-30 | $2.45M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $766.00K 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | -$1.68M 10-Q/A · filed 2011-09-07 | |||
| 2010-09-30 | -$259.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | -$1.99M 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | -$1.73M 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |